Loading patent…
AssigneeGlaxo Group Limited
InventorsTejinder Kaur Bhinder, Susannah Karen Ford, Volker Germaschewski, Alan Peter Lewis, Mark Brian Pepys
Estimating the term…
The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.
A humanised antibody, comprising SEQ ID NO:1 (CDRH1), SEQ ID NO:2 (CDRH2), SEQ ID NO:3 (CDRH3), SEQ ID NO:4 (CDRL1), SEQ ID NO:5 (CDRL2), and SEQ ID NO:6 (CDRL3), which binds to serum amyloid P component (SAP).
A humanised antibody, which specifically binds to SAP and comprises a heavy chain variable region as shown in SEQ ID NO:28;
A humanised antibody, which specifically binds to SAP and comprises a heavy chain as shown in SEQ ID NO:62;
Dependencies are inferred from the claim text.